A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids

Status:	Completed
Conditions:	Renal Impairment / Chronic Kidney Disease
Therapuetic Areas:	Nephrology / Urology
Healthy:	No
Age Range:	18 - Any
Updated:	10/14/2017
Start Date:	January 2007
End Date:	June 2013

Belatacept Conversion Trial in Renal Transplantation

The purpose of this study is to learn if conversion to belatacept from cyclosporine or
tacrolimus will preserve kidney function in people who have had a kidney transplant. The
safety and tolerability of this treatment will also be studied

Key Inclusion Criteria:

- Men and women age 18 and older

- 6-36 months after kidney transplant receiving cyclosporine or tacrolimus

- calculated GFR ≥35 and ≤75mL/min/1.73 m²

- subjects must have completed 1 year in the IM103-010ST and remained on study treatment
(Long Term Extension)

Key Exclusion Criteria:

- Significant infection

- acute rejection within 3 months

- prior graft loss due to rejection

- pregnancy

- positive crossmatch

We found this trial at

sites

University of Chicago

5801 South Ellis Avenue
Chicago, Illinois 60637

773.702.1234